Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 11/20 | 0.45 |
| ▸ | F7 | P08709 | 7/20 | 0.45 |
| ▸ | F3 | P13726 | 7/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | MASP2 | O00187 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 4/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6732975 | 1.00 | F2 (0.45) | F2F7F3PRSS1PRSS2 | |
| SCHEMBL6733639 | 0.84 | F2 (0.45) | F2F7F3PRSS1 | |
| SCHEMBL6733644 | 0.84 | F2 (0.45) | F2F7F3PRSS1 | |
| SCHEMBL6734250 | 0.79 | F2 (0.44) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6995649 | 0.78 | F2 (0.56) | F2PRSS1PRSS2PRSS3MASP2 | |
| SCHEMBL7003096 | 0.78 | F2 (0.56) | F2PRSS1PRSS2PRSS3MASP2 | |
| SCHEMBL6998939 | 0.78 | F2 (0.56) | F2PRSS1PRSS2PRSS3MASP2 | |
| SCHEMBL7000534 | 0.78 | F2 (0.45) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL6737271 | 0.77 | F2 (0.49) | F2F7F3PRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL7996215 | 0.77 | F2 (0.56) | F2PRSS1PRSS2PRSS3MASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686358-B2 | ANTICOAGULANTS; CARDOVISCULAR DISORDERS | LES LABORATOIRES SERVIER (FR) | 2004-02-03 | — | — | US | claimed |
| US-20020111341-A1 | Bicyclic amino-pyrazinone compounds | LES LABORATOIRES SERVIER (FR) | 2002-08-15 | — | — | US | claimed |
| EP-1215213-A2 | Bicyclic amino-pyrazone derivatives, their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-06-19 | — | — | EP | claimed |
| US-6686358-B2 | ANTICOAGULANTS; CARDOVISCULAR DISORDERS | LES LABORATOIRES SERVIER (FR) | 2004-02-03 | — | — | US | disclosed |
| US-20020111341-A1 | Bicyclic amino-pyrazinone compounds | LES LABORATOIRES SERVIER (FR) | 2002-08-15 | — | — | US | disclosed |
| EP-1215213-A2 | Bicyclic amino-pyrazone derivatives, their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111341-A1 | Bicyclic amino-pyrazinone compounds | CTRL, PRSS3, PRSS1 | F2 125/4885F7 1465/4885F3 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.